Clinical Trials 下面列出了当前开展的临床试验。409 研究 Cancer (仅限开放研究). 根据地点、状态和其他条件对此研究列表进行过滤。 A Study to Explore Tumor Biology in Metastatic Esophageal and Gastric Cancer Patients Rochester, Minn. The purpose of this study is to explore various biomarkers in the post-treatment tissue of patients who have responded to cancer therapy and compare it to the biopsy performed prior to cancer treatment. A Study to Assess Endometrial Cancer Recurrence in Patients After 36 Months Rochester, Minn. The purpose of this study is to assess the 36-month incidence of pelvic/non-vaginal recurrence among patients with surgical stage I intermediate-risk endometrial cancer. Eligible patients presenting with apparent uterine confined grade 1, 2, or 3 endometrioid endometrial cancer will undergo standard-of-care primary surgical treatment with a cervical injection of indocyanine green (ICG) dye for SLN mapping, a total hysterectomy, removal of the adnexae and staging with sentinel node mapping and pelvic washings. The final assessment for inclusion in the follow-up part of the study will be determined from the results of the final hysterectomy and staging pathology report to ensure bilaterally negative pelvic sentinel nodes and a surgical stage I endometrioid endometrial cancer grade 1 or 2 with 50% or more uterine myoinvasion or grade 3 with less than 50% uterine myoinvasion. Women meeting this criteria will comprise the study cohort and be followed for three years. A Study to Evaluate the Safety and Tolerability of HMPL-306 to Treat Advanced or Metastatic Solid Tumors with IDH Mutations Rochester, Minn. The purpose of this study is to evaluate the safety, tolerability, and preliminary effectiveness of HMPL-306 in advanced or metastatic solid tumors with IDH mutation. Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Subjects who received at least one GM T cell infusion, will be asked to roll-over to this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol. A Study to Develop and Maintain a Registry of Specimens from Patients with Bladder Cancer Jacksonville, Fla. The purpose of this study is to develop and maintain a registry of blood and urine specimens of patients who have been treated for bladder cancer. A Study to Evaluate Regional Radiotherapy in Biomarker Low-Risk Node Positive Breast Cancer Jacksonville, Fla. The purpose of this study is to compare the effects on low-risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back. A Study to Evaluate the Safety, Tolerability, and Determine the Optimal Dose for the Expansion Cohorts of VSV-IFNβ-NIS in Combination with Pembrolizumab in Patients with Refractory Solid Tumors Rochester, Minn. The purpose of this study is to determine the safety of VSV-IFNβ-NIS in combination with pembrolizumab, followed by expansion to examine effectiveness of combination therapy in patients with refractory Non-Small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC). A Study to Evaluate MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to characterize the safety and tolerability of MRTX849 in patients having advanced solid tumor malignancies with KRAS G12C mutation. Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to test whether a short course of aspirin can change the markers of inflammation in patients who have a benign finding within five years of their last pregnancy, and possibly reduce their risk of future breast cancer. A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor Rochester, Minn. This phase III trial compares memantine to usual treatment in treating patients with brain tumors that are newly diagnosed or has come back (recurrent). Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary brain tumor. Pagination 临床研究 PrevPrevious Page Go to page 2525 Go to page 2626 Go to page 2727 Go to page 2828 Go to page 2929 NextNext Page 医疗专业人员 Cancer clinical-trials